DALLAS, Texas — Two new trials examining the utility of genetic testing to guide warfarin dosing have come to divergent conclusions. One, the EU Pharmacogenetics of Anticoagulant Therapy (EU-PACT) ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback